Pittsburgh Football Star Battles Lymphoma Diagnosis

Pittsburgh Panthers running back James Conner is back at practice after receiving a Hodgkin's lymphoma diagnosis in December of 2015.

Conner was seen in a video tweeted by Pitt's head coach Pat Narduzzi on Saturday, doing drills with the rest of his teammates.

"The drill was sloppy but it was the 1st time doing that drill since knee surgery and chemo treatments, I will be in great shape game day!" Conner tweeted last week.

Since his diagnosis, Conner has been through several rounds of chemo treatment, reported Fox Sports.

'I choose not to fear cancer'

Conner admits that after receiving his diagnosis, the fear struck.

"When I heard those words -`You have cancer' - I admit I was scared," Conner said. "But after thinking about it for a bit, I realized that fear is a choice. I choose to not fear cancer. I choose to fight it and I will win."

Narduzzi says he doesn't doubt Conner will beat cancer with the help of his community, his fans and his team.

"We are all going to be right beside him every step of the way," Narduzzi said. "And the day that he is declared cancer free, we will all celebrate like we do after one of his patented touchdown runs."

Source: Fox Sports

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap